Age-related islet inflammation marks the proliferative decline of pancreatic beta-cells in zebrafish

  1. Sharan Janjuha
  2. Sumeet Pal Singh
  3. Anastasia Tsakmaki
  4. S Neda Mousavy Gharavy
  5. Priyanka Murawala
  6. Judith Konantz
  7. Sarah Birke
  8. David J Hodson
  9. Guy A Rutter
  10. Gavin A Bewick
  11. Nikolay Ninov  Is a corresponding author
  1. Technische Universität Dresden, Germany
  2. King's College London, United Kingdom
  3. Imperial College London, United Kingdom
  4. University of Birmingham, United Kingdom

Abstract

The pancreatic islet, a cellular community harboring the insulin-producing beta-cells, is known to undergo age-related alterations. However, only a handful of signals associated with aging have been identified. By comparing beta-cells from younger and older zebrafish, here we show that the aging islets exhibit signs of chronic inflammation. These include recruitment of tnfα-expressing macrophages and the activation of NF-kB signaling in beta-cells. Using a transgenic reporter, we show that NF-kB activity is undetectable in juvenile beta-cells, whereas cells from older fish exhibit heterogeneous NF-kB activity. We link this heterogeneity to differences in gene expression and proliferation. Beta-cells with high NF-kB signaling proliferate significantly less compared to their neighbors with low activity. The NF-kB signalinghi cells also exhibit premature upregulation of socs2, an age-related gene that inhibits beta-cell proliferation. Together, our results show that NF-kB activity marks the asynchronous decline in beta-cell proliferation with advancing age.

Data availability

The following data sets were generated

Article and author information

Author details

  1. Sharan Janjuha

    Paul Langerhans Institute Dresden of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Sumeet Pal Singh

    Centre for Regenerative Therapies, Technische Universität Dresden, Dresden, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5154-3318
  3. Anastasia Tsakmaki

    Diabetes Research Group, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. S Neda Mousavy Gharavy

    Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology, and Metabolism and Consortium for Islet Cell Biology and Diabetes, Department of Medicine, Imperial College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Priyanka Murawala

    Centre for Regenerative Therapies, Technische Universität Dresden, Dresden, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Judith Konantz

    Centre for Regenerative Therapies, Technische Universität Dresden, Dresden, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Sarah Birke

    Centre for Regenerative Therapies, Technische Universität Dresden, Dresden, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. David J Hodson

    Centre for Endocrinology, Diabetes, and Metabolism and Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8641-8568
  9. Guy A Rutter

    Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology, and Metabolism and Consortium for Islet Cell Biology and Diabetes, Department of Medicine, Imperial College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Gavin A Bewick

    Diabetes Research Group, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4335-8403
  11. Nikolay Ninov

    Center for Regenerative Therapies, Technische Universität Dresden, Dresden, Germany
    For correspondence
    nikolay.ninov@tu-dresden.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3286-6100

Funding

DFG-Center for Regenerative Therapies Dresden

  • Nikolay Ninov

German Center for Diabetes Research

  • Nikolay Ninov

Deutsche Forschungsgemeinschaft

  • Nikolay Ninov

European Foundation for the Study of Diabetes

  • Nikolay Ninov

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Marianne Bronner, California Institute of Technology, United States

Ethics

Animal experimentation: Experiments were conducted in accordance with the Animal Welfare Act and with permissionof the Landesdirektion Sachsen, Germany (AZ 24-9168, TV38/2015, A12/2016, A5/2017).

Version history

  1. Received: October 23, 2017
  2. Accepted: April 5, 2018
  3. Accepted Manuscript published: April 6, 2018 (version 1)
  4. Accepted Manuscript updated: April 10, 2018 (version 2)
  5. Version of Record published: May 9, 2018 (version 3)

Copyright

© 2018, Janjuha et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,864
    views
  • 633
    downloads
  • 25
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sharan Janjuha
  2. Sumeet Pal Singh
  3. Anastasia Tsakmaki
  4. S Neda Mousavy Gharavy
  5. Priyanka Murawala
  6. Judith Konantz
  7. Sarah Birke
  8. David J Hodson
  9. Guy A Rutter
  10. Gavin A Bewick
  11. Nikolay Ninov
(2018)
Age-related islet inflammation marks the proliferative decline of pancreatic beta-cells in zebrafish
eLife 7:e32965.
https://doi.org/10.7554/eLife.32965

Share this article

https://doi.org/10.7554/eLife.32965

Further reading

    1. Cancer Biology
    2. Cell Biology
    Dongyue Jiao, Huiru Sun ... Kun Gao
    Research Article

    Enhanced protein synthesis is a crucial molecular mechanism that allows cancer cells to survive, proliferate, metastasize, and develop resistance to anti-cancer treatments, and often arises as a consequence of increased signaling flux channeled to mRNA-bearing eukaryotic initiation factor 4F (eIF4F). However, the post-translational regulation of eIF4A1, an ATP-dependent RNA helicase and subunit of the eIF4F complex, is still poorly understood. Here, we demonstrate that IBTK, a substrate-binding adaptor of the Cullin 3-RING ubiquitin ligase (CRL3) complex, interacts with eIF4A1. The non-degradative ubiquitination of eIF4A1 catalyzed by the CRL3IBTK complex promotes cap-dependent translational initiation, nascent protein synthesis, oncogene expression, and cervical tumor cell growth both in vivo and in vitro. Moreover, we show that mTORC1 and S6K1, two key regulators of protein synthesis, directly phosphorylate IBTK to augment eIF4A1 ubiquitination and sustained oncogenic translation. This link between the CRL3IBTK complex and the mTORC1/S6K1 signaling pathway, which is frequently dysregulated in cancer, represents a promising target for anti-cancer therapies.

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Natalia Dolgova, Eva-Maria E Uhlemann ... Oleg Y Dmitriev
    Research Article Updated

    Mediator of ERBB2-driven cell motility 1 (MEMO1) is an evolutionary conserved protein implicated in many biological processes; however, its primary molecular function remains unknown. Importantly, MEMO1 is overexpressed in many types of cancer and was shown to modulate breast cancer metastasis through altered cell motility. To better understand the function of MEMO1 in cancer cells, we analyzed genetic interactions of MEMO1 using gene essentiality data from 1028 cancer cell lines and found multiple iron-related genes exhibiting genetic relationships with MEMO1. We experimentally confirmed several interactions between MEMO1 and iron-related proteins in living cells, most notably, transferrin receptor 2 (TFR2), mitoferrin-2 (SLC25A28), and the global iron response regulator IRP1 (ACO1). These interactions indicate that cells with high-MEMO1 expression levels are hypersensitive to the disruptions in iron distribution. Our data also indicate that MEMO1 is involved in ferroptosis and is linked to iron supply to mitochondria. We have found that purified MEMO1 binds iron with high affinity under redox conditions mimicking intracellular environment and solved MEMO1 structures in complex with iron and copper. Our work reveals that the iron coordination mode in MEMO1 is very similar to that of iron-containing extradiol dioxygenases, which also display a similar structural fold. We conclude that MEMO1 is an iron-binding protein that modulates iron homeostasis in cancer cells.